Key statistics
On Thursday, ARS Pharmaceuticals Inc (SPRY:NMQ) closed at 13.38, -27.71% below its 52-week high of 18.51, set on Nov 11, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 13.55 |
---|---|
High | 13.74 |
Low | 13.01 |
Bid | 13.38 |
Offer | 13.89 |
Previous close | 13.55 |
Average volume | 1.73m |
---|---|
Shares outstanding | 96.94m |
Free float | 74.44m |
P/E (TTM) | -- |
Market cap | 1.30bn USD |
EPS (TTM) | -0.5076 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
- ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
- ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
- ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences
- ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
- ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
- ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
- ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)
- ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
- EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
- ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
More ▼